MedTrace Logo

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

NCT01175148 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-06-07

Study results available
· View outcomes & findings →

Summary

Atorvastatin for prevention of acute GVHD

Conditions

  • Graft vs Host Disease

Interventions

DRUG

Atorvastatin calcium (Lipitor)

40 mg PO daily

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Mehdi Hamadani, MD · West Virginia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175148 on ClinicalTrials.gov